Indaptus Therapeutics, Inc. Depreciation
Indaptus Therapeutics, Inc. (INDP) reported Depreciation of $735 for the 12-month period ending 2024-12-31, per its 10-K filed 2026-03-17.
Financial Statements › Cash Flow › Operating Activities
us-gaap:Depreciation · last filed 2026-03-17
- Indaptus Therapeutics, Inc. depreciation for the quarter ending 2024-12-31 was $0.00, a 100.00% decline year-over-year.
- Indaptus Therapeutics, Inc. depreciation for the quarter ending 2024-09-30 was $0.00, a 100.00% decline year-over-year.
- Indaptus Therapeutics, Inc. depreciation for the quarter ending 2024-06-30 was $0.00, a 100.00% decline year-over-year.
- Indaptus Therapeutics, Inc. depreciation for the quarter ending 2024-03-31 was $735.00, a 128.97% increase year-over-year.
- Indaptus Therapeutics, Inc. depreciation for fiscal 2024 was $735.00, a 42.76% decline from fiscal 2023.
- Indaptus Therapeutics, Inc. depreciation for fiscal 2023 was $1.28K, a 27.91% decline from fiscal 2022.
- Indaptus Therapeutics, Inc. depreciation for fiscal 2022 was $1.78K, a 26.94% increase from fiscal 2021.
- Indaptus Therapeutics, Inc. depreciation for fiscal 2021 was $1.40K, a 64.67% increase from fiscal 2020.
| Period end | Depreciation 3 month | Depreciation 6 month | Depreciation 6 month as first filed | Depreciation 9 month | Depreciation 12 month |
|---|---|---|---|---|---|
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | $0.00 derived: sum of 2 quarters · filed 2026-03-17 | $0.00 derived: sum of 3 quarters · filed 2026-03-17 | $735.00 10-K · filed 2026-03-17 | |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $0.00 derived: sum of 2 quarters · filed 2025-11-12 | $735.00 10-Q · filed 2025-11-12 | $1.05K derived: sum of 4 quarters · filed 2025-11-12 | |
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13 | $735.00 10-Q · filed 2025-08-13 | $1.05K derived: sum of 3 quarters · filed 2025-08-13 | $1.38K derived: sum of 4 quarters · filed 2025-08-13 | |
| 2024-03-31 | $735.00 10-Q · filed 2025-05-14 | $1.05K derived: sum of 2 quarters · filed 2025-05-14 | $1.38K derived: sum of 3 quarters · filed 2025-05-14 | $1.70K derived: sum of 4 quarters · filed 2025-05-14 | |
| 2023-12-31 | $320.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-13 | $641.00 derived: sum of 2 quarters · filed 2025-03-13 | $963.00 derived: sum of 3 quarters · filed 2025-03-13 | $1.28K 10-K · filed 2025-03-13 | |
| 2023-09-30 | $321.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $643.00 derived: sum of 2 quarters · filed 2024-11-12 | $964.00 10-Q · filed 2024-11-12 | $1.28K derived: sum of 4 quarters · filed 2024-11-12 | |
| 2023-06-30 | $322.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-12 | $643.00 10-Q · filed 2024-08-12 | $964.00 derived: sum of 3 quarters · filed 2024-08-12 | $1.36K derived: sum of 4 quarters · filed 2024-08-12 | |
| 2023-03-31 | $321.00 10-Q · filed 2024-05-08 | $642.00 derived: sum of 2 quarters · filed 2024-05-08 | $1.03K derived: sum of 3 quarters · filed 2024-05-08 | $1.57K derived: sum of 4 quarters · filed 2024-05-08 | |
| 2022-12-31 | $321.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-13 | $713.00 derived: sum of 2 quarters · filed 2024-03-13 | $1.25K derived: sum of 3 quarters · filed 2024-03-13 | $1.78K 10-K · filed 2024-03-13 | |
| 2022-09-30 | $392.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-06 | $926.00 derived: sum of 2 quarters · filed 2023-11-06 | $1.46K 10-Q · filed 2023-11-06 | $2.00K derived: sum of 4 quarters · filed 2023-11-06 | |
| 2022-06-30 | $534.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | $1.07K 10-Q · filed 2023-08-14 | $1.60K derived: sum of 3 quarters · filed 2023-08-14 | $2.04K derived: sum of 4 quarters · filed 2023-08-14 | |
| 2022-03-31 | $534.00 10-Q · filed 2023-05-11 | $1.07K derived: sum of 2 quarters · filed 2023-05-11 | $1.51K derived: sum of 3 quarters · filed 2023-05-11 | $1.72K derived: sum of 4 quarters · filed 2023-05-11 | |
| 2021-12-31 | $535.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-17 | $977.00 derived: sum of 2 quarters · filed 2023-03-17 | $1.19K derived: sum of 3 quarters · filed 2023-03-17 | $1.40K 10-K · filed 2023-03-17 | |
| 2021-09-30 | $442.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | $655.00 derived: sum of 2 quarters · filed 2022-11-10 | $868.00 10-Q · filed 2022-11-10 | $1.08K derived: sum of 4 quarters · filed 2022-11-10 | |
| 2021-06-30 | $213.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | $426.00 10-Q · filed 2022-08-08 | $1.18M 10-Q · filed 2021-08-16 | $639.00 derived: sum of 3 quarters · filed 2022-08-08 | -$609.72K derived: sum of 4 quarters · filed 2022-08-08 |
| 2021-03-31 | $213.00 10-Q · filed 2022-05-12 | $426.00 derived: sum of 2 quarters · filed 2022-05-12 | -$609.93K derived: sum of 3 quarters · filed 2022-05-12 | ||
| 2020-12-31 | $213.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-21 | -$610.15K derived: sum of 2 quarters · filed 2022-03-21 | $852.00 10-K · filed 2022-03-21 | ||
| 2020-09-30 | -$610.36K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-15 | $639.00 10-Q · filed 2021-11-15 | |||
| 2020-06-30 | $611.00K 10-Q · filed 2021-08-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| ARVINAS, INC. (ARVN) | United States | $0.510B | 58.38 |
| PUMA BIOTECHNOLOGY, INC. (PBYI) | United States | $0.507B | 15.53 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |